Archive for January, 2008

Too much basic science?

Wednesday, January 30th, 2008

DB of Med Rants has written a series of interesting posts on how to reform the premed curriculum and hints at changes in the medical basic science courses. He has made general recommendations rather than a detailed description of course content. Although I would likely agree with many of the changes he has in mind and certainly respect his extensive expertise and experience as a medical educator I have a few concerns.

His proposals would streamline the basic science portion of the curriculum and encourage a well rounded education in the humanities. He and some of his commenters bemoan the “hard core” basic science courses (organic chemistry is frequently cited) which do not seem, in any direct way, to make one a better doctor. The same could be said, of course, for the humanities. Both content areas are important parts of a solid background for the practice of medicine but neither helps a doctor decide which antibiotic to give or what type of IV fluids to run. Both are important, but in less direct and tangible ways.

My concerns are two fold. First, with basic sciences already being de-emphasized we may be going down a slippery slope. As an example of where this type of thinking may lead consider an article in BMJ from several years ago with these suggestions for the medical school of the future:

From day one the focus of the course will be on “whole patient medicine,” which is to be based on holistic consultations with patients in their real contexts. There will be no preclinical-clinical divide, and gone will be the days of freestanding courses in biochemistry, physiology, and anatomy.

A number of schools, apparently, have already adopted this model to one degree or another with problem based learning and other means of integrating the basic science and the clinical portions of the curriculum. This style of learning could be effective. However, the BMJ piece goes on with suggestions which raise concerns that the basic sciences would be slighted:

There will be no exams in anatomy, physiology, or biochemistry, and no one will need to learn by rote the entire Krebs cycle or the names of all those little holes in the skull. All students will have to demonstrate the critical appraisal skills of evidence based practice.

No exams in anatomy, physiology or biochem? I’m sure this isn’t the type of curriculum change DB has in mind but it seems to be the direction things are heading.

More from the BMJ article:

The modular nature of the course will provide a common pathway to careers across the whole spectrum of the health profession from medicine and nursing to management and health promotion. Having learnt together as students in a range of disciplines, our graduates will be well equipped to learn both with and from each other and to continue lifelong interprofessional learning.

The article notes that physicians and allied health professionals would have a “common course with different exit points” implying that physicians would need to be no better trained in basic sciences than would allied health professionals.

My second concern is that medical schools may already have gone too far in reducing basic science teaching as evidenced by observations of medical students which Orac summarized nicely in a post from a couple of years ago. Given the utter credulity of many of today’s medical students toward quackery one has to wonder whether they’re learning any chemistry or physics at all. If students had even a modicum of understanding of these sciences would we be seeing promotions like this or this? Of course I could trot out many, many more examples.

I will continue to follow this debate and look forward to additional posts from DB on the subject.

Source: Too much basic science?

6 Ways To Reduce House Dust Mites

Wednesday, January 30th, 2008

Do you know that house mites are the most common trigger of asthma?

These are mites that live in house dust. It is the feces of the them that is the actual allergen that causes breathing problems.

These creatures produce feces about 20 times a day. Aside from being an allergen, the stools of these guys is light enough to float in the air, so it is easily inhaled by those of us who occupy homes and buildings.

Then, when you consider there are about 40,000 mites per speck of dust, you can imagine (even if you’d rather not) just how many of these dust mite stools enter your respiratory tract.

Your indoor environment is especially vulnerable to these creatures if you live in a humid area, or if your home is subject to humid conditions for whatever other reason.

Humid environments create the ideal habitation for them, primarily since they result in a greater food supply for these mites. Staples of their diet include plant materials, molds, and fungi. All of which thrive in humid conditions.

Asian countries are more prone to these microscopic creatures induced asthma attacks. However, there is a solution, it is to have clove near to mites infested areas.

Based on the facts mentioned above, you can see why it is so critical to take action for the specific purpose of minimizing these fellows in your home, particularly if someone in your home suffers from asthma.

In which case, we have compiled a list of 6 ways you can reduce the mites that reside in your home.

6 ways to reduce dust mites:

1. Encasings.
Bedding is the favorite home for them. This being the case, you should encase your bedding and pillows with impermeable rubber or vinyl plastic wrappings.

2. Washing
You should wash clothes and bedding regularly. Washing in 60oF water is effective, but 130 F water will kill all mites. Washing in cold water kills about 90% of them.

3. Dry Cleaning
Dry cleaning kills all of them.

4. Heating
Any type of heating will help minimize their presence. Some examples include steam-cleaning carpets, tumble-drying (drying machine), direct sunlight exposure, and electric blankets.

5. Air Conditioning
Air conditioning will dry out your indoor environment, which will reduce the food supply for mites, resulting in reduced their populations.

6. Air Purifier
Despite your best efforts to remove them from your home or other indoor environment, they are simply too numerous and reproduce too frequently to keep their numbers lowered without the aid of an air purifier.

Keep in mind though, an air filter (e.g. HEPA) will not make much of a difference. First of all, most dust mites are too small to be captured by even the best of filters. In addition, most of them will not even pass through the filter’s screen anyway.

Despite manufacturer’s claims that their units complete so many air exchanges per hour, or filter so many square feet per hour, these are mostly based on theoretical calculations. The reality is that most pollutants in a given room or home will not pass through a small, stationary filter.

You are better off with a negative ion and ozone generator. Negative ions and ozone are much more effective at purifying air than a filter, due to the fact that they can remove pollatants from the air that are as much as 300 times smaller than the smallest particle a filter can remove.

Plus, they can be emitted throughout your home, so they are more thorough in the area they cover. Negative ions and ozone are also capable of penetrating walls, furnishings, bedding, etc. to destroy these mites and their stools.

About the Author
Eddy has a site which shares how he managed to discover a simple yet hidden way on treating asthma that guarantees to relieve you anytime. Get a free report and articles at http://www.uniqueasthmatreatmentsecrets.com.

0 comments:

Older Post Home Subscribe to: Post Comments (Atom)

Health news

Loading…

Enter your email address:

Delivered by FeedBurner


About allergy

Allergy is hign sensitivity to certain substances such as foods, microorganisms, animal, hair, pollen, dust mites or medicines.


Allergy Archive

  • ▼ 2008 (18)
    • ▼ January (18)
      • 6 Ways To Reduce House Dust Mites
      • News : Mother killed by tomato allergy
      • Dealing With A Cat Allergy
      • Herbal Allergy Treatment
      • Life With A Gluten Allergy
      • Undue Trouble: Airborne Allergy
      • Allergies and Asthma - Differences and Similaritie…
      • Finding the Right Allergy Relief
      • Get To Know The Different Forms Of Skin Allergies
      • Cure Your Allergy
      • Wheat Allergy And Celiac Disease
      • Allergy Relief - What Can You Do?
      • Allergy Relief
      • Vega Therapy for Allergy
      • Rotation Diet for Allergy
      • Children With A Wheat Allergy
      • Allergy Tests Effectiveness
      • Allergies - Allergy Shots

My Favourite Blogs

  • Hair regrow Tips
  • Breast Information
  • YOKEY : BLOGGER

http://allergycare.blogspot.com is blog about allergy such as allergy treatment, allergy relief, allergy symptoms.

Source: 6 Ways To Reduce House Dust Mites

The eyes Tells It All

Wednesday, January 30th, 2008

Using the radiocarbon dating method and special proteins in the lens of the eye, scientists at the University of Copenhagen and Aarhus can now establish, with relatively high precision, when a person was born. This provides a useful tool for forensic researchers who can use it to establish the date of birth of an unidentified body and could also have further consequences for health science research. The findings appear in the online, open-access journal PLoS ONE on January 30……..

Original post by Health news from medicineworld.org

Source: The eyes Tells It All

Collaboration to improve the UK’s health

Wednesday, January 30th, 2008
  Printer Friendly   

 Email to a Friend

 

A collaboration between the Universities of Bristol, Cardiff and Swansea has been awarded £5 million by the UK Clinical Research Collaboration (UKCRC) to establish a Centre of Excellence for research into public health.

The Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer) will bring together experts from a range of disciplines to tackle public health issues including diet and nutrition, physical activity, and alcohol, tobacco and drugs.

The Centre will receive up to £5m over 5 years to create new academic posts and develop strong training and career development programmes.  It will be led by Professor Laurence Moore of the Cardiff Institute for Society, Health and Ethics, with Professor Rona Campbell of Bristol University’s Department of Social Medicine as co-director.

The funding will also provide the technical staff, IT systems, equipment, administrative support, research facilities and other infrastructure needed to support high quality research.

Professor Campbell said: “We are delighted to have secured this funding.  The Centre will enable world-class experts from a diverse range of backgrounds to come together and conduct the kind of research that will make a significant impact on the health of the nation. 

“There have been profound improvements in health and life expectancy over the last century but the UK still faces challenges to improve public health and ensure that, as a society, we enjoy longer and healthier lives. This Centre will produce high quality research to help policy makers deal with public health issues in an informed and practical way.”

Four other Centres of Excellence, based in Newcastle, Belfast, Cambridge and Nottingham, were also awarded grants under the same initiative. 

A group of funders came together under the umbrella of the UKCRC to provide a total of £20m.  They are the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Health and Social Care Research & Development Office for Northern Ireland, Medical Research Council, National Institute for Health Research, Wales Office of Research and Development - Welsh Assembly Government and the Wellcome Trust.

A collaboration between the Universities of Bristol, Cardiff and Swansea has been awarded £5 million by the UK Clinical Research Collaboration (UKCRC) to establish a Centre of Excellence for research into public health.

The Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer) will bring together experts from a range of disciplines to tackle public health issues including diet and nutrition, physical activity, and alcohol, tobacco and drugs.

The Centre will receive up to £5m over 5 years to create new academic posts and develop strong training and career development programmes.  It will be led by Professor Laurence Moore of the Cardiff Institute for Society, Health and Ethics, with Professor Rona Campbell of Bristol University’s Department of Social Medicine as co-director.

The funding will also provide the technical staff, IT systems, equipment, administrative support, research facilities and other infrastructure needed to support high quality research.

Professor Campbell said: “We are delighted to have secured this funding.  The Centre will enable world-class experts from a diverse range of backgrounds to come together and conduct the kind of research that will make a significant impact on the health of the nation. 

“There have been profound improvements in health and life expectancy over the last century but the UK still faces challenges to improve public health and ensure that, as a society, we enjoy longer and healthier lives. This Centre will produce high quality research to help policy makers deal with public health issues in an informed and practical way.”

Four other Centres of Excellence, based in Newcastle, Belfast, Cambridge and Nottingham, were also awarded grants under the same initiative. 

A group of funders came together under the umbrella of the UKCRC to provide a total of £20m.  They are the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Health and Social Care Research & Development Office for Northern Ireland, Medical Research Council, National Institute for Health Research, Wales Office of Research and Development - Welsh Assembly Government and the Wellcome Trust.

Source: Collaboration to improve the UK’s health

Link Between Severe Acne and Prostate Cancer

Wednesday, January 30th, 2008

(Ivanhoe Newswire) — A higher risk of prostate cancer may be linked to severe acne.

New research from Johns Hopkins Bloomberg School of Public Health in Baltimore finds men who took tetracycline — an antibiotic used to treat severe acne — for four years or longer were 70 percent more likely to develop prostate cancer over a 10-year period than men who had taken the drug, or had taken it for a shorter time.

But the study’s authors urge caution in interpreting their findings. They note the small number of participants who had used tetracycline for at least four years — 0.5-percent of the 34,629 men in the study — the indirect assessment of severe acne, and the fact that acne can have several causes.

The research looked at the link between severe acne and prostate cancer because recent studies found the acne-related bacterium Propionibacterium acnes in one third of prostate samples taken from men with prostate cancer. The tissue containing P. acnes was more likely to be inflamed. Inflammation is believed to be an important part of the development of prostate cancer.

Researchers say it is unlikely tetracycline itself would raise the risk of prostate cancer. They believe one possible explanation for the acne-prostate cancer link is that men who develop severe acne may be more likely to have stronger inflammatory immune responses when P. acnes goes into the prostate.

Sign up for a free weekly e-mail called First to Know by clicking here.

Source: Link Between Severe Acne and Prostate Cancer

Device Zeroes in on Small Breast Tumors

Tuesday, January 29th, 2008

A new medical imager for detecting and guiding the biopsy of suspicious breast cancer lesions is capable of spotting tumors that are half the size of the smallest ones detected by standard imaging systems, as per a new study. The results of initial testing of the PEM/PET system, designed and constructed by researchers at the Department of Energy’s Thomas Jefferson National Accelerator Facility, West Virginia University School of Medicine and the University of Maryland School of Medicine would be reported in the journal Physics in Medicine and Biology on Feb. 7……..

Original post by Health news from medicineworld.org

Source: Device Zeroes in on Small Breast Tumors

Diuretics Excel in Drug Comparison Trial

Tuesday, January 29th, 2008

Diuretics were linked to reduced heart disease in a drug comparison trial involving 23,077 people with both hypertension and the metabolic syndrome, a cluster of risk factors for heart disease, report scientists from The University of Texas School of Public Health and Case Western Reserve University in the Jan. 28 issue of the Archives of Internal Medicine, one of the JAMA/Archives journals. The cardiac benefits connected with diuretics were especially pronounced in blacks, who have a high occurence rate of hypertension or hypertension……..

Original post by Health news from medicineworld.org

Source: Diuretics Excel in Drug Comparison Trial

Smaller pancreatic tumors greatly increase survival odds

Tuesday, January 29th, 2008
  Printer Friendly   

 Email to a Friend

 

The odds of surviving cancer of the pancreas increase dramatically for patients whose tumors are smallest, according to a new study by researchers at Saint Louis University and the M.D. Anderson Cancer Center in Houston - the first study to specifically evaluate the link between tumor size and survival rates for one of the most common and deadly cancers.

The findings - in the current edition of Pancreas (www.pancreasjournal.com) - vividly underscore the importance of early diagnosis of pancreatic cancer, the researchers said.

“Even though it seems intuitive and was supported by preliminary observations from earlier studies, for the first time we now have evidence that a progressive decrease in the size of a pancreatic tumor at the time of diagnosis improves patient outcomes rather dramatically,” said Banke Agarwal, M.D., Associate Professor of gastroenterology at the Saint Louis University School of Medicine and lead author of the study.

“These data emphasize the benefit and the need of finding and diagnosing tumors in the pancreas as early as possible,” Agarwal added. “In order to make progress against pancreatic cancer, we have to redouble our efforts to identify symptoms that are associated with the early stages of the disease.”

Pancreatic cancer is the fourth most common cancer in the United States and one of the most deadly, responsible for more than 33,000 deaths a year, according to the National Institutes of Health.

Despite many advances in the fight against other cancers in recent years, the prognosis for patients diagnosed with the pancreatic cancer has remained extremely poor. That’s largely because the cancer is frequently not suspected and is difficult to diagnose in its early stages, when most people are asymptomatic or have non-specific symptoms that are easily ignored or attributed to other diseases.

The study looked at 65 patients who were diagnosed with pancreatic cancer at the M.D. Anderson Cancer in Houston between December 2000 and December 2001. Their average age was 67 years old; 38 were men.

Researchers found a striking correlation between a patient’s prognosis and the size of their tumor at the time of diagnosis.

Of the 12 patients whose tumors were 20 millimeters or smaller, their median survival after diagnosis was 17.2 months. For those with tumors 21-25 mm, median survival was 12.3 months. For those with tumors 26-30 mm, median survival was 8.5 months. And for those with tumors larger than 30 mm, median survival was 7.6 months. Of those patients whose tumors were 20 mm or smaller, two were still alive after 48 months; none of the patients with tumors larger than 30 mm were alive after 36 months.

Unfortunately, while the patients with the smallest tumors had the highest rates of survival, they were relatively small in number. Only 12 patients - or 18 percent - had tumors 20 mm or smaller. By contrast, the largest group of patients - 27, or 42 percent - had tumors larger than 30 mm.

In addition, the average tumor size of patients in the study was 32.9 mm - well above the threshold at which survival rates are lowest. That figure is roughly comparable to an average tumor size of about 30 mm among pancreatic cancer patients in general, according to the study.

“These numbers illustrate why we’ve made so little progress in improving outcomes for people who are diagnosed with pancreatic cancer - we’re not finding their tumors until they’re too big and it’s too late,” Agarwal said. “We know we have a much better chance of helping someone survive pancreatic cancer if it’s caught early and their tumor is small.”

Major advances in imaging technology in recent years have greatly improved physicians’ ability to diagnose progressively smaller pancreatic tumors. This hasn’t led to earlier diagnosis, however, because patients generally don’t get to the doctor until symptoms appear - and by then it’s too late.

Agarwal said researchers will need to focus on finding ways to identify people who should be screened early for pancreatic cancer. Screening of the general population for the disease hasn’t proven effective - but screening of people with a family history of pancreatic cancer is under active investigation, he said.

In addition, preliminary data from other studies have shown that elderly people who’ve been recently diagnosed with diabetes or depression have a higher likelihood of pancreatic cancer - providing another avenue for researchers to explore, Agarwal said.

Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first medical degree west of the Mississippi River. The school educates physicians and biomedical scientists, conducts medical research, and provides health care on a local, national and international level. Research at the school seeks new cures and treatments in five key areas: cancer, liver disease, heart/lung disease, aging and brain disease, and infectious disease.

Source: Smaller pancreatic tumors greatly increase survival odds

Over-the-counter eardrops may cause hearing loss or damage

Tuesday, January 29th, 2008

The Montreal Children’s Hospital of the MUHC recommends these products be used with extreme caution

MONTREAL, Jan 28, 2008 - A new study, led by researchers at The Montreal Children’s Hospital (MCH) of the MUHC, has revealed that certain over-the-counter earwax softeners can cause severe inflammation and damage to the eardrum and inner ear. The results of the study, recently published in The Laryngoscope, suggest that use of these medications should be discouraged.

“Patients often complain that wax is blocking their ears and is causing discomfort and sometimes deafness,” says Dr. Sam Daniel principal investigator of the study and director of McGill Auditory Sciences Laboratory at The Children’s. “Over-the-counter earwax softeners are used to breakup and disperse this excess wax. However, the effects of these medications on the cells of the ear had not been thoroughly analyzed.”

“Because some of these products are readily available to the public without a consultation with or prescription from a physician, it is important to make sure they are safe to use. Our study shows that in a well-established animal model, one such product, Cerumenex, is in fact, toxic to the cells of the ear,” says Dr. Daniel.

Dr. Daniel and his team studied the impact of Cerumenex on hearing. In addition, overall toxicity in the outer ear and changes in the nerve cells of the inner ear were analyzed.

“Harmful effects to many of the cells were observed after only one dose,” says Dr. Melvin Schloss co-author and MCH Director of Otolaryngology. “We observed reduced hearing, severe inflammation, and lesions to the nerve cells.”

“We believe these findings are applicable to humans,” add Dr. Daniel. “The animal model we chose has been widely used to test toxicity. In addition, this model has a very similar hearing mechanism. Overall, our findings suggest that Cerumenex has a toxic potential and it should be used with caution.”

The Montreal Children’s Hospital is the pediatric teaching hospital of the McGill University Health Centre (MUHC). The institution is a leader in the care and treatment of sick infants, children, and adolescents from across Quebec. The Montreal Children’s Hospital provides a high level and broad scope of health care services, and provides ultra specialized care in many fields including: cardiology and cardiac surgery; neurology and neurosurgery, traumatology; genetic research; psychiatry and child development and musculoskeletal conditions, including orthopedics and rheumatology. Fully bilingual and multicultural, the institution respectfully serves an increasingly diverse community in more than 50 languages.

www.thechildren.com

For more information please contact:
Lisa Dutton
Manager, Public Relations and Communications MCH
(514) 412-4307
lisa.dutton@muhc.mcgill.ca

Latest Pharma News…

Source: Over-the-counter eardrops may cause hearing loss or damage

Medical Research Council and GSK to identify new therapeutic targets from genetic association studies

Tuesday, January 29th, 2008
  Printer Friendly   

 Email to a Friend

 

The Medical Research Council (MRC) and GlaxoSmithKline (GSK) have announced the creation of a jointly funded programme seeking to identify and validate genes associated with common human diseases. A key aim of the programme will be to translate these observations into new drug targets and biomarkers of disease.

The MRC and GSK will each invest £1 million in the programme over the next three years, which will pilot a new way of collaborative working between the two organisations. It will bring together academic and industrial expertise and resources in areas of mutual interest through joint funding and sharing from large databases and sample collections held by the partners. The collaboration will speed the translation of genetic insights into new concepts for therapy and other benefits for patients.

Projects funded through the programme will bring together MRC and GSK resources to study the role of genes in common human diseases through genetic association studies. This approach of combining data sets is increasingly recognised as necessary in order to increase the statistical robustness of studies and to enable the definitive identification of genes at the root of a disease. As part of the collaboration, GSK will make extensive data acquired from large disease-related and population-based genetic studies available. The GSK collections have considerable potential to better link genetic traits to detailed variations in phenotypes.

Sir Leszek Borysiewicz, Chief Executive of the Medical Research Council, said: “This type of project is a testament to the collaborative working relationship which exists between public and private research in the UK and allows both to thrive. By making the most of existing investments, the MRC can support the very best research into the patterns and causes of disease. Collaborating to produce larger cohorts and hence more statistically significant results, will allow us to identify genetic and other contributors to disease more quickly and maximise benefits for future patients.

Dr Patrick Vallance, Senior Vice President, Drug Discovery, GaxoSmithKline, said: “The genetics of human diseases has come of age and GSK wants to make the most of current knowledge and research to significantly impact treatment options. We have worked hard to collect and refine our data but we now need to take a bold step forwards and work with others to uncover the new disease targets and genetic variations that are useful to inform drug discovery and development. GSK is looking forward to pioneering this novel and exciting working partnership with the MRC which we believe models openness and collaboration. We hope other industry groups will see the power of pooling knowledge in this way and consider how they too can work productively with academic partners. Lon Cardon is GSK’s new head of Genetics who will lead for GSK on this collaboration.”

The programme will be managed by a joint MRC-GSK Steering Group, which will oversee the funding and progress of projects. To mark the creation of this partnership two major awards are being announced.

The first will support research on depression where the genetic basis is complicated and the underlying mechanisms not well understood. This study aims to identify genes involved in susceptibility to depression by combining very large samples of thousands of white European subjects with well identified depression.

“An important genetic contribution to depression is well established and understanding the molecular basis of this will provide vital clues to tailoring existing treatment to individual needs and discovering novel targets for new safer, more effective medications,” said Professor Peter McGuffin who will lead the research at the MRC Social, Genetic and Developmental Psychiatry Centre based at the Institute of Psychiatry, London.

The second project is focused on using large population-based cohorts to identify new genetic variants associated with obesity and related metabolic disorders and to more precisely localise the causal variant underlying the genetic signal.

“Being able to bring together carefully characterised cohorts, such as EPIC-Norfolk and the Lausanne cohort, will allow us to make the most of the latest genomic technology and help us identify key genetic risk factors for common metabolic disorders,” said Professor Nick Wareham who will lead the investigation at the MRC Epidemiology Unit in Cambridge.

Source: Medical Research Council and GSK to identify new therapeutic targets from genetic association studies